

```
AAC see augmentative and alternative
                                                              capsular-putaminal, 482
    communication
                                                              classification, 475-478
achromatopsia, 460-461
                                                              conduction, 476, 481
Action Research Arm Test (ARAT), 137-138, 237, 239
                                                              cortical, 476, 478-482
activities of daily living (AOL) scales, 138-141
                                                              C-Speak program, 491, 492
activity scales see specific scales
                                                              drug treatments, 491–493
                                                              global, 476, 480, 505, 511
acupuncture, efficacy on motor/functional
    recovery, 172
                                                              language-speech recovery, 485-489, 493-495, 496
"adaptive strategies", 346, 364-367
                                                              language-speech therapy, 128, 489-491, 493-494,
age, risk factor in stroke, 5, , 7, 431
                                                                  516-518
Agency for Health Care Policy and Research
                                                              prevalence, 474-475
    rehabilitation guidelines, 197-205
                                                              syndromes, 474-482, 476, 505
agitation, 270-271
                                                              thalamic, 482
agnosia, visual see visual agnosia
                                                              transcortical, 476, 479-480, 481, 505
akathisia, 270-271
                                                              Wernicke's aphasia, 126, 128, 476, 480, 505, 511
                                                              see also apraxia; dysarthria; language-speech
akinetopsia, 461
alcohol consumption, risk factor in stroke, 5, 11-12
                                                                  disorders
alien hand syndrome, 272-273
                                                           apnea
                                                              central, 585
Alpha-Tocopherol, Beta-carotene Cancer Prevention
    Study, 15
                                                              obstructive, 585, 585-586, 586-587, 588, 589-590
amphetamines, impact on ischemic recovery, 70
                                                              see breathing, sleep disordered
analgesics, use in pain treatment, 307
                                                           apraxia, 505
angioplasty, carotid as stroke treatment, 22
                                                              of gait, 262
                                                              of speech, 479, 511
anosognia, 524
anticonvulsants, use in pain treatment, 307
                                                           ARAT see Action Research Arm Test
antidepressants
                                                           Aronson, A. E., 483
  effect of fluoxetine on motor recovery, 128
                                                           Ashworth Scale (muscle tone rating), 288, 289
                                                           aspirin, use in stroke reduction, 17-18, 19, 28, 30,
  use in pain treatment, 307
antispastic drugs, 299
                                                           assessment
antithrombotic drugs, use in stroke prevention, 17-
                                                              in early rehabilitation, 198-205, 199, 202
     18, 27-29
                                                              in health interventions, 135-143
anxiety, role in sexual dysfunction, 438, 446-447
                                                              tools see measurement tools
aphasia, 510-511
                                                              work rehabilitation programs, 629-630
  anomic, 476, 481-482, 505, 511
                                                              see also specific impairments
                                                            Assessment of Motor and Process Skills, 142
  and brain anatomy, 126
  Broca's, 476, 478–479, 505, 510
                                                           Assessment of Quality of Life Instrument, 147-148
  Boston Diagnostic Aphasia Examination,
                                                           asterixis, 269-270
       475-478, 476
                                                           Asymptomatic Carotid Atherosclerosis Study, 21-22
```



Atherosclerosis Risk in the Communities Study, 9,	biology post-stroke, 51, 51–56, 52
10, 11	damage, and sleep disordered breathing, 582-583
athetosis, 266–267	environmental effects in rat brain, 70-71, 72
ntrial fibrillation	see also specific brain regions
relationship to stroke incidence, 18-20	breathing, sleep disordered, 582–583
risk factor in stroke, 5, 20, 29, 29–30	and cardiovascular disease, 584–586
atrial septal aneurysm, incidence in stroke, 30	and cerebrovascular disease, 584–586, 586–589
augmentative and alternative communication, 490	Cheyne–Stokes breathing, 584
axonal growth, 52–54, 71–73	prevalence, 581–582
ixonai grown, 32 34, 71 73	treatment, 589–590
paclofen, 296–297, 301	see also apnea; insomnia
palance	British Male Doctors Study, 17–18
assessment in stroke patients, 321–324, 322,	British Regional Heart Study, 9, 10, 12
358–359	Broca's aphasia, 476, 478–479, 505, 510
	Brown, J. R., 483
measurement scales, 324–326, , 327, 328, 337–339,	
338	Brunnstrom concept, 371–372
retraining post-stroke, 325, 370–377	BWSTT see body weight supported treadmill training
and vestibular deficits, 354	
see also posture	C-Speak aphasia program, 491, 492
Balint's syndrome, 457, 505, 522	Cancer Prevention Study II, 12
Barthel Index, 48, 138–139, 290, 422,	cardiovascular disease
BDAE see Boston Diagnostic Aphasia Examination	contribution of sleep disordered breathing,
Beck Depression Inventory, 570	584–586,
penign paroxysmal positional vertigo (BPPV), 348	relationship to stroke incidence, 18–20, 27–29, 30
therapies, 367–369, 368	risk factor in stroke, 5, 20, 29, 29–31
penzodiazepines, 295–296	see also cerebrovascular diseases; specific disorders
Berg Balance Scales, 325, 370–377	Cardiovascular Heart Study, 14, 24
Bezafibrate Infarction Prevention Study, 11	carotid endarterectomy, as stroke treatment, 21-22
oladder	carotid stenosis, risk factor in stroke, 21-22
control during early rehabilitation, 200-201	Carr, J. H., 229
diagnosis of disorders, 418, , 419, 420, 423-424	casts (orthotics), 235-236
physiology 1008(12)-1010(20)	catalepsy, 262
see also incontinence, urinary; urine storage	"catastrophic reaction" syndrome, 525
disorders; voiding disorders	central amblyopia, 460
olepharospasm, 271	central nervous system post-stroke
olindsight, 457–458	anatomy, 49–51
plood pressure	biology, 51–56
risk factor and treatment, 6–8, 7	central nervous system stimulation, 308
role in stroke prevention, 25–27	central post-stroke pain, 303-309
Bobath method, 227–228, 293, 371–372	cerebral reorganization, 125–130
pody weight supported treadmill training (BWSTT),	cerebrovascular accidents see strokes
174–176	cerebrovascular diseases, contribution of sleep
Boston Diagnostic Aphasia Examination (BDAE),	disordered breathing, 584–586, 586–589
475–478, 476	CHADS <sub>2</sub> index, 20
potulinium toxin, 241–243, 300–301	Charcot–Wildbrand syndrome, 594
powels	Checklist of Individual Strength (fatigue measure),
assessment of function, 431	570
management of functioning, 431–432	Cheyne–Stokes breathing, 584
	-
physiology, 429–430,	see also breathing, sleep disordered
see also incontinence, fecal	Chlamudia programaniae, and strake incidence 24
BPPV see benign paroxysmal positional vertigo	Chlamydia pneumoniae, and stroke incidence, 24
oraces (orthotics), 235–236	cholesterol
orain	reduction of, 27
anatomy post-stroke, 49–51, 90–95, 91, 94, 95, 96,	risk factor in stroke, 5, 9–10
124–130	chorea/ballism, 266



chronometric assessment, neurological, 328–329, 338	deficits see impairments
CIMT see constraint-induced movement therapy	dementia (post-stroke), 545-547
circadian rhythms, 581	dependency, 543, 543-544
clinical test of sensory interaction and balance	mortality from, 544
(CTSIB), 337–339, 338	predictors, 541–542
clopidogrel, use in stroke reduction, 28	prevalence, 538-541, 539, 540
cognition, spatiality, 344	prognosis, 49, 542–545
cognitive dysfunction, 203	treatment, 547–549
case study, 640	depression (post-stroke)
emotional changes, 523-526	classification, 557-558
in brain hemispheres, 503–512, 504, 505	diagnosis, 556-559, 557
in limbic and paralimbic areas, 512–513	drug treatments, 564–566, 565
recovery and therapy, 522-523	influence on recovery, 564
relationship with depression, 561–564	management during rehabilitation, 203
see also specific impairments	prevalence, 559
cognitive syndromes (ischemic stroke), 505	relationship with cognitive/neurological deficits
color blindness, 460–461	561–564
coma, indicator of stoke severity, 422	relationship with fatigue, 569
communication disorders see language-speech	role of lesion location, 559–561
disorders	diabetes mellitus, risk factor in stroke, 5, 8–9, 421
community rehabilitation services	diballism, 266
classification, 216	diet
community teams, 215, 216–217, 220–223	management in dysphagic patients, 409–410
impact on clinical outcomes, 192, 193	risk factor in stroke, 5, 13–16
importance and need, 209–210	see also nutrition
nature and development, 213	
± .	Different Strokes, 642 disabilities <i>see</i> impairments
theoretical models, 213–216	*
see also early-discharge rehabilitation schemes	disability movement, the
compensatory behavior, 49, 108–109	views on stroke care provision, 212–213
dysphagia management, 404, 407–408	see also independent living movement
complex regional pain syndrome, 309	discharge planning (hospital), 203–205, 204
compulsive behaviors, 270–271	see also community rehabilitation services;
conductive education, role in motor learning,	early-discharge rehabilitation schemes
228–229	dizziness see vertigo
constraint-induced movement therapy (CIMT), 107,	domiciliary rehabilitation services see community
177–179, 238–240	rehabilitation services
context/task specific rehabilitation, 372-374	dreaming, loss of, 594, 595
continence in stroke patients	drug treatments
assessment, 425,	for central pain, 306–307
factors determining, 424	effect on sexual functioning, 444
see also incontinence, fecal; incontinence, urinary	impact on ischemic recovery, 70
continuous positive airway pressure (CPAP), 587–589	use in stroke reduction, 17–18
contraceptives, oral and stroke incidence, 5, 16	see also specific drugs; ailments
Copenhagen City Heart Study, 10	DSM-IV diagnosis criteria, 557-558
cortical blindness see visual disorders	Dynamic Gait Index, 325-326
"covert practice" (mental practice), 243-244	dysarthria
CPAP see continuous positive airway pressure	ataxic, 484, 485
CTSIB see clinical test of sensory interaction and balance	characteristics, 482-484, 485
cystometry, 418, 419, 420, 423–424	flaccid, 485
	language-speech recovery 1180(14)-1182(2)
dantrolene, 297–298	pure/isolated, 484, 485
Darley, F. L., 483	spastic, 485
deafness, idiopathic, 347	unilateral upper motor neuron, 483–484
defecation, physiology, 430	see also aphasia; language–speech disorders
see also bowels; incontinence, fecal	dyskinesia, 268–273



dysphagia, 200	strength training, 231–232
assessment, 401–410, 404, 405–406,	treadmill training, 174-176, 240-241
counselling, 410-411	see also physiotherapy; robot-mediated therapy;
diet, 409–410	expectation, role in sexual dysfunction, 447-448
effect of stroke, 398-400	eye disorders see visual disorders
indicator of stoke severity, 422	.,
swallowing ability, 400–401	feces, incontinence see incontinence, fecal
treatment, 400–401, 403–405, 404, 406–411, 409	falls, prevention, 369–370
see also swallowing ability	FAM see Functional Assessment Measure
dystonia, 263–264	family history, risk factor in stroke, 5, 6
1 12 1 1 1 1 1 1 1 2 2 1 1 2 2 2 2 2 2	fatigue
early-discharge rehabilitation schemes, 216–217,	definition, 567
217–220	relationship with depression, 569
impact on clinical outcomes, 192, 193	fatigue post-stroke, 569–571, 572
early rehabilitation units, 192–196, 197	and lesion location, 571–572
Early Treatment Diabetic Retinopathy Study, 18	assessment, 568
Edinburgh Artery Study, 23	relationship with depression, 569
education, conductive and motor learning, 228–229	feedback
elderly	role in rehabilitation, 57, 58
prevalence of dementia with stroke, 539, 540	see also electromyographic biofeedback
treatment of hypertension, 7	fetal tissue, transplantation, 73-75
electrical stimulation (physiotherapy intervention),	fiberoptic endoscopic examination of swallow,
168–170, 236–237, 308	405–406
electromyographic biofeedback, 167–168	fiber, dietary and stroke incidence, 14-15
emotional changes	FIM see Functional Independence Measure
cognitive recovery, 523–526	finger extension, efficacy of functional electrical
determinants, 558	stimulation, 169
emotionalism, 525	fluoxetine, effect on motor recovery, 128
employment program	FMA see Fugl-Meyer Assessment
re-entry, 625, 634	focal activity scales, 137–138
supported, 625–627, 629–634	folic acid, relationship to stroke incidence, 23
stroke rehabilitation, 625, 634	Framingham Study, 9–10, 13, 14, 21, 546
empowerment (rehabilitation principle), 624–625	Frenchay Activities Index (FAI), 142, 150
	"frontal disequilibrium", 262
endarterectomy, carotid as stroke treatment, 21–22	÷
endocrine system, role in sexual functioning, 445	frontal lobe syndromes
environment	and urinary incontinence, 417
impact on brain anatomy of rats, 70–71, 72	cognitive failures, 503–510, 504
impact on recovery, 69	Fugl-Meyer Assessment (FMA), 325, 609–610
erection (sexual) dysfunction, 441–442	function, recovery of, 106–109, 165–167
ethnicity, risk factor in stroke, 5, 5–6	see also motor function
Europe, stroke mortality, 2, 2–3, 5–6	function measurement see specific impairments
EuroQoL, 147	and tool
evaluation see assessment	Functional Assessment Measure, 140
evidence, clinical in diagnosis, 161	Functional electrical stimulation, 168–170
excitability, post-stroke, 106	finger extension, 169
exercise	functional imaging
aerobic, 171–172	role in rehabilitation, 90–95
constraint-induced movement therapy, 107,	role in neural network reorganization, 97-104
177–179, 238–240	Functional Independence Measure (FIM), 48,
dysphagia treatment, 408–409	139–141, 290, 608
endurance training and recovery, 171–174	"functional reach test", 325
fitness programs and recovery, 171–172	
impact on functional abilities, 170–171	gait disorders, 262
movement imagery, 243–244	apraxia, 262
practice and reinforcement, 56–61	cautious, 352
*	· · · · · · · · · · · · · · · · · · ·



gait disorders (cont.)	hormone-replacement therapy, 16-17
Dynamic Gait Index, 325-326	hospital outreach teams, 214
frontal, 262	hypercholesterolemia see cholesterol
"isolated gait ignition failure", 262	hyperkinetic syndromes, 263-273
"magnetic", 262	hypersexuality, prevalence among neurological
mirror movements, 270	patients, 438–439
Petren's, 262	hypersomnia, 591–593, 592
senile gait, 262	hypertension as risk factor in stroke, 5, 6–8, 7, 421
therapy, 170, 174–176, 176–177	Hypertension Optimal Treatment Study, 8, 18
in vascular parkinsonism, 261	hypertonia, 233–236
see also balance; locomotion; mobility; posture; walking	hypokinetic syndromes, 259–263
gender, risk factor in stroke, 5	imaging, see functional imaging
gene expression (post-ischemic), 68–69	impairments
general practitioners, involvement in community	biological controls, 51, 52
rehabilitation, 211–212, 214–215, 216–223	cognitive see cognitive dysfunction
genetics, risk factor in stroke, 6	late onset, 210–211
Gerstmann's syndrome, 505, 511	measurement scales, 290
"get up and go" test, 137, 325	musculoskeletal, 361–362
glucose intolerance, risk factor in stroke, 8–9	neurological see neurological dysfunction
guidelines (clinical and rehabilitation)	and post-stroke depression, 562–563
Agency for Health Care Policy & Research	recovery post-stroke, 47, 48, 56–61
guidelines, 197–205, 199	see also specific impairments
impact on stroke recovery, 165	incontinence, fecal
see also under specific impairments	prevalence, 429–430
	risk factors, 421, 430
Hamrin Activities Index, 142	incontinence, urinary
handicaps see impairments	assessment of, 425,
Harvard Alumni Study, 12	definition, 415–416
head-eye coordination (vestibular rehabilitation),	during early rehabilitation, 200-201
359–360	indicator of stoke severity, 422
health interventions, measurement, 135-143	management of, 424-428
health practitioners, involvement in community	predictor of disability, 421-422,
rehabilitation, 211-212, 214-216, 216-223	prevalence, 418, 419–421
Health Professionals Follow-up Study, 14, 15	risk factors, 421,
health services, structure and organization, 212	independent living movement, the, 216
see also community rehabilitation services; hospital	see also disability movement
outreach teams; rehabilitation services	infarction, cerebral see strokes
heart disease see cerebrovascular disease	infection and inflammation
Heart Outcomes Prevention Evaluation Study, 8, 15, 25	relationship to stroke incidence, 24
Heart Protection Study, 15	risk factor in stroke, 5
hemianopia, 47, 48, 56–61, 458	insomnia, 593
hemichorea–hemiballism, 265–267	Instrumental Activities of Daily Living scale, 141–143
hemi-inattention, 202	International Classification of Functioning, Disability
	and Health, 135
hemineglect, 464–465, 505, 511–512 hemisphere lesion and cognitive dysfunction,	International Classification of Impairments,
	*
503–512, 504, 505	Disabilities and Handicaps, 135
left, 510–511	. 1 1
right, 504, 511–512	job placement, 630–631
heredity, risk factor in stroke, 5, 6	W. D. W. H. L.C. D.
high density lipoprotein, 10–11	Kaiser Permanent Medical Care Program, 16
home-based rehabilitation services see community	
rehabilitation services	language–speech disorders
homocysteine overload, 5, 7, 22–23	characteristics, 202–203
Honolulu Heart Program, 8, 11	indicator of stoke severity, 422



recovery from, 485-489, 493-495, 496	mood changes see emotional changes
therapy, 128, 489–491, 492, 493–494, 516–518	mortality, stroke
see also aphasia; apraxia; dysarthria	case-fatalities, 4
anguage function (brain anatomy), 126	incidence, 3–4, 544, 544–545
axatives, 431–432	statistics, 2, 2–4, 3, 5–6
flearned non-use", 107	Motor Activity Log, 177
earning, conductive and motor learning, 228–229	motor function
eft hemisphere see hemisphere, left	assessment in stroke patients, 321–324, 322
esions, location of	brain anatomy, 124–126, 127–128
impact on use of robot therapy, 611–614, 612, 613,	see also mobility; measurement tools; walking
role in post-stroke depression, 559–561	motor learning
role in post-stroke fatigue, 571–572	Carr and Shepherd program, 229–230
esions, stroke	role of conductive education, 228–229
and aphasia, 474–475, 476, 478–482	see also exercise
and dysarthria, 482–484, 485	Motor Power Score, 609
and dysphagia, 398	motor speech disorders (Darley), 483
effect on body stability, 345	Motor Status Score, 609,
and language–speech recovery, 485–489	movement, physical and sensory
and urinary incontinence, 418	characteristics post-stroke, 108–109
Lhermitte's peducular hallucinosis, 594	coordination with posture, 345–346
ifestyle, risk factor in stroke, 11–16	as guide to recovery level, 102
ipids, risk factor in stroke, 10–11	retraining, 362–367, 364
ipoprotein (a), 10	role in rehabilitation, 107–108, 109
ocomotion	see also mobility; walking
neurological control, 50–51	movement disorders
see also balance; mobility; posture; walking	hyperkinetic, 263–273
1 \ '' 262	hypokinetic, 259–263
narche à petits pas, 262	see also spasticity
neasurement	"movement imagery", 243–244
balance, 324–326, 327	movements, mirror, 270
health interventions and outcomes, 135–143	Multinational Monitoring of Trends and
posture, 328–329, 331, 332, 334, 338	Determinants in Cardiovascular Disease
robotic, 614–616,	(MONICA) Project, 2,
stroke severity, 422	Multiple Risk Factor Intervention Trial, 9–10
neasurement tools	muscle strength
communicability, 136	characteristics, 61–62
health outcomes, 136–143	impact on motor function, 171
quality of life, 144–150	role in body stability, 343
reliability, 136, 140–141	see also physiotherapy exercises;
validity, 136, 140–141	muscle tone
simplicity, 136	definition, 233
see also specific tools and impairments	physiotherapy interventions, 233–236
nedical practitioners	tone intensity scales, 288–290, 289,
involvement in community rehabilitation,	see also physiotherapy
211–212, 214–216, 216–223	myoclonus, 269
see also nurse practitioners; occupational	myorrhythmia, 269
therapists; physiotherapists	
Melodic Intonation Therapy, 494, 516–517	National Health Service (NHS) UK, 212
memory failures, cognitive recovery, 522-523	National Institute of Health Stroke Scale 8.4
mental practice", 243–244	neglect
mitral valve prolapse, as cause of stroke, 30	hemineglect, 464–465, 505, 511–512
mobility	"learned non-use", 107
"get up and go" test, 137, 325	visuospatial, 505, 519–521
role in rehabilitation, 107-108, 109, 201-202	nerve blocks, in antispastic treatment, 299-300
see also balance; gait; posture; walking	nervous system, role in pain experience, 309



networks, neural	Oswestry Scale of Grading, 289
anatomy post-stroke, 99, 103, 105, 106	outcomes assessment see measurement tools
plasticity of, 51, 52	outpatient services
reorganization post-stroke, 97-106	option for stroke rehabilitation, 213-214
neural cells	see also community rehabilitation services; early
proliferation, 75–77	discharge rehabilitation schemes
transplantation, 74–75	
"neurodevelopmental treatment" (Bobath), 227–228	pain
"neurofacilitation", 227	central post-stroke pain, 303–309
neurological dysfunction	classification, 302–303
impact on intimate relationships, 448–452, 450,	complex regional pain syndrome, 309
relationship with depression, 561–564	efficacy of functional electrical stimulation, 169–
neuronal precursor response, 55–56	170
new technologies, use in rehabilitation, 244	pain management
Newcastle Community Multiple Sclerosis Team, 215	drug treatments, 306–307
Niemi Quality of Life Scale, 150	electrical stimulation, 236–237, 308
Nine Hole Peg Test, 138	neurosurgery, 308
Norre, M. E. 13.65	see also specific treatments
North American Study of Carotid Endarterectomy	paraballism, 266
Trial, 21	paralysis, indicator of stoke severity, 422
Nottingham Extended Activities of Daily Living	parasomnia, 593–594
Scale, 142	parkinsonism, vascular, 259–261, 262
Nottingham Health Profile, 145–146	partners, non-disabled
nurse practitioners, 211, 215–216	impact of disability on relationship, 450,
see also medical practitioners; occupational	PASS see Postural Assessment Scale for Stroke
	Patients
therapists; physiotherapists Nurses' Health Study, 13, 14, 15	passive smoking, risk factor in stroke, 11
nutrition	
foodstuffs, 13–16, 23	patent foramen ovale, risk factor in stroke, 29, 30 Perfetti method, 293
management in dysphagic patients, 409–410	Petö, A., 228
relationship to stroke incidence, 13, 13–16,	Petren's gait, 262
14–15, 23	pharmacotherapy see drug treatments
vitamins, 15–16, 23	pharyngeal manometry, use in dysphagic
see also diet	assessment, 406
1 2 116 4 1 4 1 0	physical activity, relationship to stroke incidence,
obesity, risk factor in stroke, 9	12–13
obstructive sleep apnea, 585, 585–586, 586–587, 588,	"physical conditioning", 231–232
589–590	Physicians' Health Study, 12, 14, 17–18
see also breathing, sleep disordered	physiotherapists and community rehabilitation, 211,
occupational therapists	214–215, 216–223
dysphagia management, 410	see also medical practitioners; nurse practitioners;
involvement in community rehabilitation, 211,	occupational therapists
214–215, 216–223	physiotherapy
see also medical practitioners; nurse practitioners;	advantages, 108–109
physiotherapists	case study, 246–248, 638–639
Odstock Dropped Foot Stimulator, 237	efficacy, 230–231
omega 3 intake, relationship with stroke incidence,	future developments, 244–245
13–14	history, 226–230
oral contraceptives, relationship with stroke	see also exercise; occupational therapy; orthoses;
incidence, 5, 16	dysphagia; spasticity
orofacial dyskinesia, 273	plasticity (brain), 90–97
orthopedic approach to physiotherapy	pneumonia, relationship with stroke incidence, 24
influence on rehabilitation, 227	pontine lesions, and urinary incontinence, 418
orthoses, 235–236, 293–294	post-stroke depression see depression
see also physiotherapy; walking aids	posterior hemisphere (post-stroke)



cognitive failures, 504, 512	clinical outcomes, 190–192
Postural Assessment Scale for Stroke Patients (PASS),	definition, 192–196
326, 327	management of depression, 203
posture	role of practice and reinforcement, 47, 48, 56-61
adaptive behaviors, 346	sensory stimulation, 375-376, 408
assessment, 339-340, 358-359, 360-361	skin care, 199–200
coordination with movement, 345-346	see also exercise; mobilization; recovery, stroke
disturbance post-stroke, 320-321, 340-342,	rehabilitation, vocational
341-342	criteria enabling success, 627-629
effect on dysphagia, 404	definition, 623-624
measurement of, 326-329, 330, 331, 332, 332-336,	principles, 624
334, 336–337, 338,	see also employment programs (vocational
stabiliation, 342–345	rehabilitation)
verticality, 322, 329-332, 331	rehabilitation services, 163-179
see also balance; gait; mobility; posturography	efficacy of physiotherapy, 230-231
postunography	impact of early and intensive rehabilitation, 165-
dynamic, 337–339	167, 192–196, 197
static, 334, 334–336	patient opinion, 212-213
prasopagnosia, 463–464	self-help organizations, 642
primary care teams, option for stroke rehabilitation,	see also community rehabilitation services; early-
214–215	discharge rehabilitation schemes; hospital
Primary Care Trusts, 212	outreach teams reinforcement and practice i
primary prevention project, 15, 18	rehabilitation, 56–61
progenitor cells	relationships, intimate
proliferation, 75–77	impact on sexual functioning, 445-448
transplantation, 75	management of problems, 450–452, 451,
promoting aphasic communicative effectiveness	social impact of neurological dysfunction, 446,
(PACE), 517	448–450, 450
PSD see depression	see also partners, non-disabled
psychology, importance in pain treatment, 306	restitution (cerebral), 48
"pusher behavior", 341–342	of motor function post-stroke, 127-128
	rhythmic auditory stimulation, 176–177
quality of life	rhythmic positional feedback, 176–177
definition, 143–144	Rivermead Activities of Daily Living Assessment,
measurement of, 144–150	141–142
Quality of Life Index – Stroke Version, 149–150	robot-mediated therapy, 244
•	benefits, 609–614, 610, 613,
race, risk factor in stroke, 5, 5-6	characteristics, 605, 616-619
Rankin Scale, 141	effect on recovery, 605-609, 607
ratings scales see measurement tools	impact of lesion location, 611-614, 613,
recovery, stroke, 47, 48, 56–61, 88–89, 92, 513–514	measurement capacity, 614–616,
acute-stage pathophysiology, 190	"rocking chair paradigm", 330, 331, 336–337
brain anatomy, 124–130	
cerebral activity, 101–102, 106	SA-SIP 30, 149
functional activity, 106–109, 165–167	scales of functional measurement see measurement
impact of guidelines, 165	tools
impact of pre-stroke social life, 564	selegeline, 70
see also rehabilitation; survival, stroke; specific	self-help organization, 642
disorders	sensibility
recurrent stroke	of outcome measurement tools, 136
effect on dysphagia, 399-400	see also specific tools
incidence among patients with dementia, 543	sensory faculties
rehabilitation	deficits, 343–344
assessment, 197–205, 202, 204	recovery of, 47, 48, 56–61, 201–202
case study, 637–641	stimulation (stroke rehabilitation), 375–376, 408



ensory faculties (cont.)	stenosis, carotid and stroke, 21-22
use in movement retraining, 364,	stereotypy, 270
see also deafness, idiopathic; vision visual disorders	Stroke-Adapted 30-Item Version of the Sickness
Sensory Organization Balance Test, 328, 338	Impact Profile (SA-SIP30), 149
erotonergic drugs, effect on motor recovery, 128	Stroke Impact Scale (SIS), 148-149
exual dysfunction	stroke lesions see lesions, stroke
case study, 640	stroke nurses, 211, 215–216
contributory factors, 438, 445-450, 451	see also medical practitioners; occupational
female, 442–443	therapists; physiotherapists
hypersexuality, 438–439	Stroke Specific Quality of Life Scale (SSQoL), 149
male, 441–442, 443–444	stroke units and wards
management, 450-452, 451,	efficacy, 163–165
prevalence, 436–440	impact on clinical outcomes, 191-192
see also relationships, intimate	organization and structure, 192–196, 197
exual response cycle, 138	strokes
exuality	characteristics and classification, 4-5, 161
definition, 440–441, 447	epidemiology and etiology, 1
myths, 448	guidelines for risk reduction, 26
physiology, 443–445	impact on intimate relations, 448–450, 450
Shepherd, R.B., 229	incidence, 1–2, 18–20, 22–23
Short Form-36 (SF-36), 145	infratentorial and sleep—wake disorders, 596–597
Sickness Impact Profile, 146–147	measures of severity/quality of life, 136–143,
see also Stroke-Adapted 30-Item Version of the	144–150, 422
Sickness Impact Profile	mortality, 2–4, 3, 5, 5–6, 544, 544–545
kill recovery, 106–109	prevention, 25–31, 26, 198
kin care, 199–200	risk factors, 5, 6–9, 7, 9–10, 11–12, 13–16, 20,
leep disorders see apnea; breathing, sleep disordered;	21–22, 29, 29–31, 421
insomnia; hypersomnia; parainsomnia;	statistics of cases, 210
sleep–wake disorder	supratentorial and sleep–wake disorders, 596–597
leep–wake disorder (SWD), 590–597, 592,	see also cognitive dysfunction; impairments;
_	
594, 595	mortality, stroke; neurological dysfunction
leeping tablets, 295–296	stroke patients views of rehabilitation, 212–213
moking	"subcortical disequilibrium", 262
impact of cessation, 27	substitution (stroke recovery), 48–49
passive, risk factor in stroke, 11	surgical treatments see therapy, surgical
risk factor in stroke, 5, 11	survival, stroke
noring	impact of clinical guidelines, 165
and cerebrovascular disease risk, 584–585	impact of intensive rehabilitation, 165–167
see also breathing, sleep disordered	see also recovery, stroke
ocial life (pre-stroke)influence on recovery, 564	"swallow maneuvers", 409
pasm, hemifacial 672(11)	swallowing difficulty see dysphagia
pasticity	SWD see sleep-wake disorder
definition, 233, 287–288	Swiss Heart Study, 23
exacerbating factors, 289	synaptic plasticity, 52
measurement scales, 288–290	Systolic Hypertension in the Elderly Program, 7
physiotherapy for, 233–236, 292–293	
role in body stabilization, 342–343	Tardieu scale, 289
treatment, 241–243, 290–302, 299	task/context-specific rehabilitation, 372-374
peech disorders see language-speech disorders	technology in rehabilitation, 244
peech function (brain anatomy), 126	Test Evaluant Les Members Surperieurs des
SQoL see Stroke Specific Quality of Life Scale	Personnes Agees (TEMPA), 138
tem cells	therapists, and community rehabilitation, 211,
immortalized, 74-75	214–215, 216–223
response, 55–56	therapy
transplantation, 74–75	program, 173–174



selection criteria for functional/motor recovery,	vertigo, 346–347, 348–349
173–174	assessment, 360,
see also specific therapies and disorders	benign paroxysmal positional, 364–367, 367–369,
herapy, surgical	368
antispastic, 302	cervical, 348–349, 356–357
dysphagia management, 410	impact on patient recovery, 349-352
pain therapy, 308	positional, 348–349
tracheostomy, 400–401	treatment, 352–369, 368
Thrombosis Prevention Trial, 18	visual, 356
iclopidine, 28	see also vestibular neuritis
l'inetti assessment, 325	vestibular
izanidine, 298	impairments, 354, 354–356
ΓMS see transcranial magnetic stimulation	rehabilitation, 357, 357–361, 366
one (muscle)	vestibular neuritis, 347, 347–348
definition, 233	Veterans Affair High-Density Lipoprotein
physiotherapy interventions, 233-236	Intervention Trial, 11
tone intensity scales, 288–290	virtual reality, use in rehabilitation, 244
ourrettism, 271	vision
racheostomy (post-stroke), 400-401	neurobiology, 456-457
raining see exercise; physiotheraphy	use in movement retraining, 364
ranquillizers, 295–296	visual agnosia, 461-463, 505
ranscranial magnetic stimulation (TMS)	cognitive recovery, 522
impact on recovery, 95–97	cognitive therapy, 522
role in recovery, 89	visual analogue scales, 150
role in neural network reorganization, 104–106	visual disorders
ranscutaneous electrical nerve stimulation	blindsight, 457-458
(TENS), 308	cognitive recovery, 521–522
Fransnational Case Control study of Oral	cognitive therapy, 522
Contraceptives and Health, 16	color blindness, 460–461
ransplantation	cortical blindness, 457
fetal tissue, 73–75	exercises (vestibular rehabilitation), 366
neural cells, 74–75	field disorders, 458–460
progenitor cells, 75	localization disorders, 464
readmill, see exercise, treadmill	rehabilitation post-stroke, 457–466
reatment see therapy	relaxation techniques (vestibular rehabilitation),
remor, 267–268	366–367
repidant abasia, 262	visuospatial neglect, 505, 519–521
Frial in Old Patients with Hypertension, 7	visuospatial training, 464
riglycerides, 11	Vitamin Intervention for Stroke Prevention Study, 23
rigiyeerides, 11	•
ıltrasound	vitamins, relationship to stroke incidence, 15–16, 23 voiding disorders, 426, 427–428
	=
use in bladder disorder diagnosis, 418	see also incontinence, urinary; urine storage disorders
use in dysphagic assessment, 405	disorders
JMNS see upper motor neuron syndrome	
inilateral neglect, 202, 464–465	wake-sleep disorders see sleep-wake disorders
inilateral vestibular loss, 354, 354–355	walking
upper motor neuron syndrome (UMNS), 287,	aids in stroke rehabilitation, 377
288, 298	neurological control, 50–51
urinary catheters, risk factors, 427	recovery of, 47, 47–48, 56–61
urine incontinence see incontinence, urinary; bladdet	task-oriented practice, 59–61
urine storage disorders, 426, 427	see also balance; mobility; posture
see also bladder; voiding disorders	wards and stroke units
	efficacy, 163–165
ascular parkinsonism, 259–261, 262	impact on clinical outcomes, 191-192
verticality can poeture verticality	organization and structure 192-196 197



## 656 Index

warfarin, use in stroke reduction, 19, 28–29, 30 Wieacher syndrome, 479 Wernicke's aphasia, 476, 480, 505, 511 and brain anatomy, 126 impact of language training, 128 Women's Estrogen Stroke Trial, 17 Women's Health Initiative trial, 17 Women's Health Study, 24 work programs, 629–634 re-entry (stroke rehabilitation), 625, 634 wrist extension, efficacy of functional electrical stimulation, 169